急性冠状动脉综合征早期盐酸替罗非班治疗对血清可溶性CD40配体水平的影响  

Effect of early treatment with tirofiban hydrochloride on serum CD40 ligand level in acute coronary syndromes

作　　者：徐邦牢[1] 贝春花[1] 黎镇赐[1] 雷秀霞[1] 王蓉[1] 

机构地区：[1]广州市第一人民医院,广东广州510180

出　　处：《中国心血管杂志》2006年第2期99-100,108,共3页Chinese Journal of Cardiovascular Medicine

基　　金：广州市科技攻关计划资助项目(编号:2004Z3-E0441)

摘　　要：目的观察急性冠状动脉综合征(ACS)早期盐酸替罗非班治疗对血清可溶性CD40配体(sCD40L)水平的影响,了解盐酸替罗非班对ACS斑块稳定性和免疫炎症抑制的作用。方法143例初次确诊为ACS患者分为常规治疗组76例和盐酸替罗非班治疗组67例,用ELISA法测定143例ACS患者治疗前后血清sCD40L水平。结果盐酸替罗非班治疗组67例ACS患者治疗后血清sCD40L水平明显下降,与常规治疗组比较有显著统计学差异(P<0.01)。结论ACS患者早期予以盐酸替罗非班治疗,可明显降低血清炎症因子水平,从而改善该病进程。Objective To observe the effect of early treatment with tirofihan hydrochloride on serum CD40 ligand level in acute coronary syndromes（ACS） and to understand the role of tirofiban hydrochloride in plaque stability and immunological inflammation inhibition in ACS. Methods 143 cases of initially diagnosed as ACS were divided into two groups. 76 cases were treated with routine medicine and 67 cases were treated with tirofihan hydrochloride plus routine medicine. Serum CD40L levels were determined by ELISA in all patients. Results Serum CD40L level was decreased significantly in patients treated with tirofihan hydrochloride as compared with that in the patients treated with routine medicine（ P 〈 0.01）. Conclusion Early treatment of ACS patients with tirofiban hydrochloride can significantly decrease serum inflammatory cytokines.

关 键 词：急性冠状动脉综合征 盐酸替罗非班 可溶性CD40配体 

分 类 号：R541.4[医药卫生—心血管疾病] R446.6[医药卫生—内科学]